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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most fatal malignancies worldwide, and CD133 is a
popular cancer stem cell (CSC) marker for HCC. CD133+ CSCs have been reported to resist conventional chemo- and
radiotherapy, but little is known about their response to immune surveillance. Interferon-gamma (IFN-γ) is one of key
cytokines that the immune system produce to eradicate cancer cells, so we investigated the function of IFN-γ on
CD133+ HCC CSCs in this study.
Methods: The response of CD133+ cells to IFN-γ was performed with functional assays (cell proliferation assay and
tumor formation in nude mice), flow cytometry, immunofluorescence staining and RNA interference.
Results: We found that IFN-γ inhibited the proliferation of cell lines with low percentage of CD133+ cells (wild-type
human cells, BEL7402, QGY7701) but it did not affect the proliferation of cell lines with high percentage of CD133+ cells
(wild-type human cells, Huh7, PLC8024) in vivo and in vitro (nude mice). Flow cytometry analysis demonstrated that
the percentage of CD133+ cells increased after IFN-γ treatment of low CD133+ cell lines. Furthermore, IFN-γ induced
the autophagy of low CD133+ cell lines to decrease proliferation.
Conclusion: CD133+ HCC CSCs resisted IFN-γ-induced autophagy, which might also be a mechanism through which
CSCs resist immune eradication.
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Background
Because it is incurable, cancer is one of the most fatal
diseases, and it affects millions of people worldwide [1].
Although significant efforts have been made by thou-
sands of clinicians and researchers, no cure for cancer
has been discovered [2–5]. Many cancers are resistance
to radiotherapy and chemotherapy or have high recur-
rence after surgery or conventional treatment [6–10].
According to modern theory, cancer cells resist conven-
tional therapy and cause recurrence due to the existence
of a population of cancer cells termed cancer stem cells
(CSCs) [11–17]. CSCs are considered the originating
cancer cells, and they comprise a very small population
of total cancer cells. However, this small population of
cancer cells is also thought to be the origin of cancer re-
currence and the primary cells that are resistant to
radiotherapy and chemotherapy.
Hepatocellular carcinoma (HCC) first develops in the
liver, and it is one of the ten most common cancers
worldwide [18]. According to research from our group
and others, CD133 is a highly recognized marker for
HCC CSCs [19, 20]. CD133+ cells have strong in vivo
tumorigenicity [19]. For example, 5 × 104 CD133+ cells
sorted from Huh7 cells could induce tumor formation in
7/9 of nude mice, while CD133- cells could not induce
tumor formation until the injecting cells up to 3 × 106
cells. CD133+ HCC CSCs were reported to be resistant
to doxorubicin and 5-fluoruracil-mediated apoptosis be-
cause of their preferential expression of the survival pro-
teins involved in the Akt/PKB and Bcl-2 pathway [21].
CD133+ liver CSCs have also been reported to be
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resistant to radiotherapy because of their high activation
of the MAPK/PI3K signaling pathway [22]. There have
been few reports about the resistance of liver CSCs to
immune eradication. However, some studies have sug-
gested that such interactions might exist between CSCs
and the immune system. For example, in an HCC nude
mouse model, we observed several tumor cells that were
surrounded by many immune cells in the local tumor re-
gion. This observation raised several questions, including
the following: What are these cells’ characteristics? Are
they liver CSCs? Because CD133 is an accepted surface
marker for liver CSC [19, 20], we stained these tumor
cells with a CD133 antibody and found that CD133+
tumor cells existed in this region.
The immune system plays a very important role in
cancer immune surveillance [23]. Interferon-gamma
(IFN-γ) is one of the most important cytokines that nat-
ural killer cells secrete to perform their defense duty in
tumor immunity and against microbe invasion [24–27].
IFN-γ is a glycosylated protein that facilitates tumor re-
jection by modulating the systemic immunity to cancer
cells. Thus, IFN-γ is a central modulator of tumor im-
munity, and it can also directly kill tumor cells by indu-
cing cell apoptosis or autophagy after binding to
receptors expressed on the tumor cell surface [28–34].
Although nude mice lack a thymus, large quantities of
IFN-γ are still secreted by NK cells or other remaining
immune cells. Thus, we investigated the direct function
of IFN-γ on CD133+ liver CSCs in this study.
Methods
HCC cell lines and cell culture
The human HCC cell line Huh7 was provided by Dr. H.
Nakabayashi, Hokkaido University School of Medicine,
Japan. HCC cell lines PLC8024, BEL7402 and QGY7701
were obtained from the Institute of Virology of the
Chinese Academy of Medical Sciences (Beijing, China).
All HCC cell lines were cultured in high-glucose DMEM
supplemented with 10 % FBS, 50 U/mL penicillin G and
50 μg/mL streptomycin under humidified conditions
containing 5 % CO2 at 37 °C. No ethics approval was re-
quired for the use of above mentioned human HCC cell
lines as it did not related to any ethics problem in the
usage and passage of them in this study.
Immunohistochemistry (IHC) staining
Paraffin-embedded, formalin-fixed nude mouse tumor
tissue sections (5-μm-thick) were deparaffinized and
rehydrated. Endogenous peroxidase activity was blocked
with 3 % hydrogen peroxide for 30 min. For antigen re-
trieval, strict serial slides were immersed in 10 mM cit-
rate buffer (pH 6.0) and boiled for 15 min in a
microwave. Non-specific binding was blocked by 5 % bo-
vine serum albumin (BSA) in phosphate buffer solution
(PBS) for 30 min. Slides were then incubated with an
antibody against human CD133 (1:100; Santa Cruz Bio-
technology, Santa Cruz, CA, USA) or isotype at 4 °C
overnight in a moist chamber. An HRP-conjugated sec-
ondary antibody was used to detect primary antibodies.
Diaminobenzidine tetrahydrochloride was used as the
visualization substrate, followed by counter staining with
hematoxylin. Positively stained cells were observed and
captured under a microscope.
Hematoxylin and eosin (H.E.) staining
Paraffin-embedded, formalin-fixed tissue sections were
deparaffinized and rehydrated. Nuclei were stained with
hematoxylin, and the cytoplasm was developed with
eosin after thorough washing.
Cell proliferation assay and foci formation
Cell growth rates were determined using a Cell Counting
Kit-8 (DOjinDO Laboratories, Japan) (CCK-8). Cells
were seeded in a 96-well plate at a density of 5 × 103
cells and incubated at 37 °C in a humidified atmosphere
containing 5 % CO2. After 24 h, cultured cells were
treated with different dosages of recombinant human
IFN-γ (rhIFN-γ) (Peprotech, Rocky Hill, NJ, USA). The
CCK-8 assay was then performed according to the man-
ufacturer’s instructions. Three independent experiments
were performed, and data were expressed as the mean ±
SD. For the focus formation assay, 1 × 103 cells were
seeded in a 6-well plate and stimulated with or without
10 ng/ml(10000 IU/ml) rhIFN-γ for 2 weeks. Media
were changed every three days. Surviving colonies were
fixed and stained with 1 % crystal violet. Three inde-
pendent experiments were performed.
Effects of IFN-γ on in vivo proliferation
The study protocol was approved by and performed in
accordance to the Committee of the Use of Live Animals
in Teaching and Research at Sun Yat-sen University
Cancer Center. 2×106 PLC8024 and 5×106BEL7402 cells
were subcutaneously injected into nude mice. After two
weeks, tumors were dissected and minced using a sterile
blade. Minced tumors were then divided into ten parts
and implanted into another ten nude mice. These ten
nude mice were randomly divided into two groups. One
group was IP injected with 20000 IU rhIFN-γ (CLON-
GAMMA, China) (to acquire the same IFN-γ concentra-
tion in vivo as that in in vitro culture) every day for four
weeks, and the other group was injected with the same
volume of buffer control. The tumor volume was mea-
sured weekly. After four weeks, mice were sacrificed and
photographed, and tumors were minced and digested as
described by Ma et al. [35] to acquire single cell suspen-
sions for flow cytometry analysis.
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Flow cytometry analysis
For flow cytometry analysis, 1 × 106 cells were acquired
and washed once before staining with their respective
antibody in 1 % BSA/PBS buffer for 30 min on ice in the
dark. The following antibodies were used: PE-CD133/2
(Miltenyi Biotec; Auburn, CA, USA), FITC-IFN-γR1
(IFN-γ receptor 1) (R&D Systems, Minneapolis, MN,
USA), APC-IFN-γR2 (IFN-γ receptor 2) (R&D Systems,
Minneapolis, MN, USA), their respective isotopes from
the same company were used as controls. Cells were an-
alyzed on a flow cytometry (FC500, Beckman).
Apoptosis analysis
1 × 106 cells were stained in binding buffer, propidium
iodide (PI) and FITC-conjugated Annexin V, as provided
by the Annexin-VFLUOS Staining Kit (Roche Diag-
nostics), according to the manufacturer’s instructions.
Cells were then analyzed by flow cytometry (FC500,
Beckman).
Immunofluorescence (IF) staining and confocal
microscopy
Cells were seeded on glass cover slips in a 6-well plate at
a density of 2 × 104 cells and incubated at 37 °C in a hu-
midified atmosphere containing 5 % CO2. After 24 h,
cultured cells were treated with or without 10 ng/mL
rhIFN-γ for 4 days. Media were changed every three
days. Cells were washed twice with PBS and fixed in 4 %
paraformaldehyde for 15 min at RT, and non-specific
binding was blocked by 5 % BSA in PBS for 30 min at
RT. Slides were incubated with a mouse antibody against
human LC3 (1:100; MBL, Japan) at 4 °C overnight in a
moist chamber. Unbound primary antibody was re-
moved by washing slides twice in PBS for 5 min each.
Alexa Fluor 488-conjugated anti-mouse immunoglobulin
secondary antibodies were used for detection. Finally,
cells were washed and mounted with mounting medium
containing DAPI (Vector Laboratories, Burlingame, CA,
USA) before being visualized by a confocal microscopy.
RNA interference (RNAi) assay
BEL7402 and QGY7701 cells were transfected with small
interference RNA (siRNA) against Atg5: Atg5 si-1: 5′-
CAAUCCCAUCCAGAGUUGCUUGUGA-3′; Atg5 si-2:
5′-AGUGAACAUCUGAGCUACCCGGAUA-3′ (Shang-
hai GenePharma, China) or a scramble control using Li-
pofectamine 2000 reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instruction.
Transfected cells were treated with 10 ng/mL rhIFN-γ
for four days; the gene silencing efficiency and autoph-
agy were measured by western blotting. Cell growth was
detected using a CCK-8 assay.
Quantitative real-time PCR (Q-PCR)
Total RNA was extracted using TRIzol Reagent (Invitro-
gen, Carlsbad, CA), and reverse transcription was per-
formed using an Advantage® RT for PCR Kit (Clontech,
Mountain View, CA) according the manufacturer’s in-
structions. For Q-PCR analysis, aliquot of double-
stranded cDNA was amplified with the primer of
CD133: (Fw: 5′-TGGATGCAGAACTTGACAACGT-3′,
Rv: 5′-ATACCTGCTACGACAGTCGTGGT-3′), or 18S:
(5′-CTCTTAGCTGAGTGTCCCGC-3′, Rv: 5′-CTGA
TCGTCTTCGAACCTCC-3′) using a SYBR Green PCR
Kit (Applied Biosystems, Carlsbad, CA) and an ABI
PRISM 7900 Sequence Detector. CD133 mRNA delta
Ct = CD133 Ct-18S Ct. All reactions were performed in
duplicate.
Western blotting (WB) analyses
Whole cell lysates were harvested with cell lysis buffer
according to the manufacturer’s instructions. Western
blotting analyses were performed with the standard
protocol using antibodies against human GAPDH (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), LC3
(Novus, Littleton, CO, USA) and P62 (Cell Signaling
Technology, Beverly, MA, USA).
Statistical analysis
Comparisons between groups were analyzed using
Student’s t-test or One-Way ANOVA for more than
two groups in the SPSS software (version 16.0). A
value of P < 0.05 (two-tailed) was considered statisti-
cally significant.
Results
CD133+ cells were detected in mice eight weeks after
HCC cell injection
To study whether cancer cells can live for long periods
of time in nude mice, 1×104 PLC8024 cells were sub-
cutaneously injected into nude mice. Eight weeks after
injection, we obtained local implanted tissues from
treated mice. We observed cancer cells surrounded by
many immune cells by H&E staining (Fig. 1). To confirm
whether HCC CSCs existed in this spot or not, we
stained tissues with the HCC CSC marker CD133. Re-
sults showed that a subset of tumor cells were CD133+
(Fig. 1), indicating that CSCs could live for long periods
of time in tested animals.
CD133+ HCC cells resisted IFN-γ-induced growth delay
As liver CSCs were surrounded by many immune cells,
we continued to explore whether they resisted to attack
induced by IFN-γ or not, which is an important cytokine
secreted by immune cells. Four HCC cell lines with dif-
ferent percentages of CD133+ cells [19] (Fig. 2a) were
treated with different dosages of rhIFN-γ. The cell
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growth rate was determined by a CCK-8 assay, and re-
sults showed that HCC cell lines with a high percentage
of CD133+ cells (Huh7 and PLC8024) were more resist-
ant to rhIFN-γ treatment than were HCC cell lines with
a low percentage of CD133+ cells (BEL7402 and
QGY7701) (Fig. 2b). Foci formation assays also demon-
strated that HCC cell lines with a high percentage of
CD133+ cells had a stronger resistance than did HCC
cell lines with a low percentage of CD133+ cells (Fig. 2c).
In vivo tumor formation assays also demonstrated that
PLC8024 cells were more resistant to IFN-γ treatment
compared with BEL7402 cells (Fig. 3).
IFN-γ treatment enriched the CD133+ cell population in
vitro and in vivo
To test whether IFN-γ treatment can enrich the CD133+
cell population or not, we determined the percentage of
CD133+ cells in BEL7402, QGY7701, Huh7 and
PLC8024 cell lines by flow cytometry and Q-PCR after
IFN-γ (10 ng/ml) treatment. Results demonstrated that
the percentage of CD133+ cells in BEL 7402 was dou-
bled and the percentage of CD133+ in QGY 7701 was
increased by seven times after IFN-γ treatment. IFN-γ
had no significant effect on PLC8024 cells. In contrast,
the percentage of CD133+ Huh7 cells slightly decreased
after IFN-γ treatment (Fig. 4a). After we found that IFN-
γ influenced differently on different HCC cell line in
vitro, we wanted to explore what happened in vivo. So
we followed to test whether IFN-γ treatment could in-
crease the CD133+ cell population in xenograft tumors
induced by PLC8024 or BEL7402 cells or not. For each
cell line, 5 xenograft nude mice were treated with or
without IFN-γ. Interestingly, the percentage of CD133+
cells significantly increased in xenograft tumors treated
with IFN-γ compared with the control tumors without
IFN-γ treatment (P < 0.05, Fig. 4b).
CD133+ cells resisted IFN-γ induced apoptosis and
autophagy
Because IFN-γ can induce tumor cell apoptosis [34], we
tested whether CSCs could resist IFN-γ-induced
apoptosis in HCC cell lines or not. The apoptotic index
was detected by flow cytometry at day 4 and 6 after
IFN-γ treatment (10 ng/ml). Results showed that IFN-γ
only induced apoptosis in QGY7701 cells (Fig. 5), sug-
gesting that BEL7402, Huh7 and PLC8024 cells were re-
sistant to IFN-γ-induced apoptosis. Because IFN-γ can
also cause cell death by inducing autophagy [35], we
next studied whether HCC CSCs could resist IFN-γ-
induced autophagy or not. Results from both immuno-
fluorescence staining (Fig. 6a) and Western blot (Fig. 6b)
analysis demonstrated that IFN-γ treatment increased
autophagy in BEL7402 and QGY7701 cells, but not in
the Huh7 and PLC8024 cells.
Atg5 knockdown prevented IFN-γ-induced autophagy in
low CD133+ HCC cell lines
To further verify that IFN-γ induced growth delay was
mediated by IFN-γ-induced autophagy, we knocked
down Atg5 expression, which is an important compo-
nent of the autophagy pathway [36, 37]. Results showed
that Atg5 knockdown prevented IFN-γ induced autoph-
agy in BEL7402 and QGY7701 (Fig. 6c). However,
knocking down Atg5 reversed IFN-γ induced growth ar-
rest in the BEL7402 cell line, but not in the QGY7701
cell line (Fig. 6d).
IFN-γ receptors were not differently expressed between
high and low CD133+ percentage HCC cell lines
Because different cell lines’ responses to IFN-γ treatment
segregated with their CD133+ cell content, we examined
whether their response could be explained by IFN-γ re-
ceptor expression or not. Thus, we detected IFN-γ re-
ceptor expression on the cell surface using flow
cytometry. Results demonstrated that cells did not have
different expression levels of IFN-γ receptors on their
surfaces (Additional file 1: Figure S1).
Discussion
CSCs have been reported to cause tumor recurrence, re-
sist chemotherapeutic reagent and radiotherapy-induced
apoptosis [21, 22]. In the current investigation, we
Fig. 1 H.E. and IHC staining of PLC8024 cells implanted tumor spots. H.E. and IHC staining for CD133 and isotype expression in strict serial
PLC8024 cells implanted tumor spot sections (400×)
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Fig. 2 CD133 expression and proliferation assay of IFN-γ-treated HCC cell lines. a Left, flow results of CD133 expression in four different cell lines.
Right, Q-PCR results of CD133 expression in four different cell lines. b CCK-8 assay of different IFN-γ dosages in various HCC cell lines. *, p < 0.05.
c Foci formation assay of four HCC cell lines treated with or without 10 ng/ml IFN-γ for two weeks. Left, representative graph; Right, summary
figure.*, p < 0.05. Representative of three independent experiments
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Fig. 3 In vivo effect of IFN-γ on PLC8024 and BEL7402 cell-implanted nude mice. a Photograph of PLC8024 and BEL7402 implanted nude mice
treated with or without IFN-γ for four weeks. b Tumor volumes in PLC8024 and BEL7402-implanted nude mice treated with or without IFN-γ,
measured weekly. *, p < 0.05
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Fig. 4 Expression of CD133+ cells after IFN-γ treatment in vitro and in vivo. a Left, representative percentage of CD133+ cells in four HCC cell lines
with or without 10 ng/ml IFN-γ treatment for four days analyzed by flow cytometry. Control, treated with buffer control; IFN-γ, treated with
10 ng/ml IFN-γ. Right, Q-PCR results of CD133 mRNA expression in four HCC cell lines with or without 10 ng/ml IFN-γ treatment for four days. C,
treated with buffer control; I, treated with 10 ng/ml IFN-γ. **, p < 0.01. Representative of three independent experiments. b Left, representative
percentage of CD133+ cells in the indicated cell line-implanted nude mice with or without IFN-γ treatment for four weeks analyzed by flow
cytometry. Right, summary figure.*, p < 0.05. Gating strategy, all gating of live tumor cells
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demonstrated that CD133+ liver CSCs resisted IFN-γ-
induced autophagy, which might be a novel defining
characteristic of liver CSCs. Of course, tumor cells that
were resistant to IFN-γ induced autophagy should not
be limited to CD133+ CSCs because we also found that
many CD133- tumor cells remained after IFN-γ treat-
ment both in vivo and in vitro. Thus, other mechanisms
or characteristics of tumor cells might exist to resist
IFN-γ-induced cell death.
In this investigation, we observed the phenomenon
that high percentage CD133+ PLC8024 cell line in vitro
changed to low percentage of CD133+ cell in vivo, which
was in accordance with what had been reported about
Huh7 [19]. The reason might be that a tumor hierarchy
existed in cancer stem cells in which the CD133+ cells
might generate CD133- tumor cells [19]. The difference
that we did not observed significant increase of CD133+
percentage in vitro in PLC8024 and observed the enrich-
ment of CD133+ cells in vivo might be that the percent-
age of PLC8024 cell line in vitro was very high and it
was hard to observe the significant increase, whereas the
in vivo CD133+ percentage was very low and it was easy
to observe the difference.
Ma et al. previously reported that either CD133- or
CD133+ cells separated by sorting maintained the nor-
mal CD133+ cell percentage level after short-term cul-
ture [19]. Furthermore, the significantly different cellular
reactions to IFN-γ treatment were not apparent until
four days in culture. Thus, we did not observe signifi-
cantly different reactions to IFN-γ treatment between
CD133+ and CD133-negative cells sorted from Huh7 or
PLC8024 cell lines (data not shown).
Fig. 5 Apoptosis analysis in four cell lines after 10 ng/ml IFN-γ treatment for the indicated times analyzed by flow cytometry. Gating strategy, all
gating of tumor cells. Representative of three independent experiments
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Fig. 6 (See legend on next page.)
Li et al. BMC Cancer  (2016) 16:15 Page 9 of 11
IFN-γ is an important component of the innate and
cellular immune systems for attacking tumors. There
have been many reports about the function of IFN-γ on
tumor cells. IFN-γ can induce the upregulation of
tumor-associated antigens, such as carcinoembryonic
antigen and TAG72, to enhance the immunogenicity of
tumor cells [38]. It can also directly induce tumor cell
apoptosis or autophagy [30, 33, 34]. In this investigation,
we found that IFN-γ can induce autophagy in low
CD133+ percentage cell lines, but not that in high
CD133+ percentage cell lines. Furthermore, we detected
an increase in the percentage of CD133+ cells in low
CD133+ percentage cell lines after IFN-γ treatment,
which suggested that CD133+ cells might resist IFN-γ
induced autophagy. These results also implied that to
completely eliminate cancer from the body, treatment
with only IFN-γ is insufficient because a portion of
CD133+ CSCs were resistant to IFN-γ. These data may
partially explain why some patients demonstrated little
or no response to IFN-γ treatment on clinic [39]. High
expression of Bcl-2 was reported to be responsible for
the apoptosis or autopahgy resistance induced by IFN-γ
in human tumor-derived endothelial cells or human lung
epithelial A549 cells [40, 41]. And Bcl-2 was also re-
ported to be high expressed in CD133+ CSCs [21], which
might be the potential mechanism of CD133+ CSCs
resisted to IFN-γ induced apoptosis and autophagy in
this study.
In this investigation, we also found that IFN-γ could
induce both apoptosis and autophagy in QGY7701 cell
line. Whereas it could only induce autophagy in
BEL7402 cell line. So IFN-γ induced cell growth delay
in QGY7701 might be due to the apoptosis and autoph-
agy induced by IFN-γ in QGY7701’s CD133- cells and
IFN-γ induced cell growth delay in BEL7402 might be
due to the autophagy induced by IFN-γ in BEL7402’s
CD133- cells. Thus, when we knocked down the ex-
pression of Atg5 in BEL7402, IFN-γ induced autophagy
was inhibited. So IFN-γ induced cell growth delay was
restored. Whereas in QGY7701 cell line, even we
blocked IFN-γ induced autophagy by knocking down
the expression of Atg5, IFN-γ could still delay their
growth by inducing the apoptosis of QGY7701’s
CD133- cells. So knocking down the expression of Atg5
could not restore IFN-γ induced cell growth delay in
QGY7701.
Conclusion
We reported for the first time that CD133+ cancer stem
cells existed in microenvironment surrounded by many
immune cells in nude mice. Further investigated ex-
plored that CD133+ CSCs could resist IFN-γ induced
autophagy in vivo and in vitro. These findings may add
new characteristics to cancer stem cells and help to ex-
plore their key role in tumor surveillance evasion.
Additional file
Additional file 1: Figure S1. Flow cytometry analysis of IFN-γ receptor
surface expression in four cell lines. The dotted lines represented the
isotype control. Representative of three independent experiments.
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